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Abstract
Background:  The time course of infarct evolution, i.e. how fast myocardial infarction (MI)
develops during coronary artery occlusion, is well known for several species, whereas no direct
evidence exists on the evolution of MI size normalized to myocardium at risk (MaR) in man. Despite
the lack of direct evidence, current literature often refers to the "golden hour" as the time during
which myocardial salvage can be accomplished by reperfusion therapy. Therefore, the aim of the
present study was to investigate how duration of myocardial ischemia affects infarct evolution in
man in relation to previous animal data. Consecutive patients with clinical signs of acute myocardial
ischemia were screened and considered for enrollment. Particular care was taken to assure
uniformity of the patients enrolled with regard to old MI, success of revascularization, collateral
flow, release of biochemical markers prior to intervention etc. Sixteen patients were ultimately
included in the study. Myocardium at risk was assessed acutely by acute Myocardial Perfusion Single
photon emission computed tomography (MPS) and by T2 imaging (T2-STIR) cardiovascular
magnetic resonance (CMR) after one week in 10 of the 16 patients. Infarct size was measured by
late gadolinium enhancement (LGE) at one week.
Results: The time to reach 50% MI of the MaR (T50) was significantly shorter in pigs (37 min), rats
(41 min) and dogs (181 min) compared to humans (288 min). There was no significant difference
in T50 when using MPS compared to T2-STIR (p = 0.53) for assessment of MaR (288 ± 23 min vs
310 ± 22 min, T50 ± standard error). The transmural extent of MI increased progressively as the
duration of ischemia increased (R2 = 0.56, p < 0.001).
Conclusion:  This is the first study to provide direct evidence of the time course of acute
myocardial infarct evolution in relation to MaR in man with first-time MI. Infarct evolution in man
is significantly slower than in pigs, rats and dogs. Furthermore, infarct evolution assessments in man
are similar when using MPS acutely and T2-STIR one week later for determination of MaR, which
significantly facilitates future clinical trials of cardioprotective therapies in acute coronary syndrome
by the use of CMR.
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Background
Final MI size is an important determinant of prognosis in
patients with acute coronary syndrome [1,2]. A major
determinant of final MI size is duration of ischemia [3],
which has been shown to affect patient outcome [2,4,5].
Acute ischemic heart disease leads by necessity to the con-
sequences of chronic ischemic heart disease unless the
acute event is treated by revascularization within "the
golden hour". The golden hour, however, is mainly
derived from retrospective uncontrolled studies of vast
patient populations using indirect techniques to assess MI
size, and may at best constitute a rough estimate of the
dependence on time for infarct evolution in man.
Whereas the time course of infarct evolution is well
known for several species [3,6-11], no direct evidence
exists on the evolution of MI size normalized to MaR in
man. Thus, our understanding of infarct biology is to a
large extent based on experimental studies and little is
known from studies in man. This is mainly because accu-
rate measurement of MI size in vivo has been difficult to
obtain in humans. Indirect methods such as ejection frac-
tion, biochemical markers of myocardial injury, ECG,
echocardiography, or Myocardial Perfusion Single photon
emission computed tomography (MPS) have previously
been used to estimate MI size. With the introduction of
late gadolinium enhancement (LGE) cardiovascular mag-
netic resonance (CMR), it is now possible to differentiate
between viable and non-viable myocardium, and thus
assessing MI size with high accuracy in vivo [12]. It has
been shown in both dogs [13] and humans [14] that abso-
lute MI size, or MI size normalized to left ventricular mass,
shows no major relation to duration of ischemia. How-
ever, in order to determine how duration of ischemia
affects MI size, it is essential to relate MI size to the
amount of myocardium subjected to ischemia, i.e. the
MaR.
Therefore, the primary aim of the present study was to
investigate how duration of ischemia affects myocardial
infarct evolution in man using automatically quantified
MPS defects and T2-weighted double inversion blood
suppressed turbo spin echo sequence (T2-STIR) for MaR
and automatically quantified MI size using LGE in
patients with first-time MI. A secondary aim was to com-
pare these findings with results from previous experimen-
tal animal studies.
Methods
Study population
The protocol and procedures were approved by the local
research ethics committee. All patients gave their written
informed consent to participate. More than 700 consecu-
tive patients with clinical signs of acute myocardial
ischemia were screened and considered for enrollment. To
be able to compare the results from the present study with
prior animal studies, strict inclusion criteria were applied
to resemble an experimental setting as much as possible.
Therefore, to be considered for inclusion, patients should
have no history of old MI, a single occluded artery fol-
lowed by successful revascularization by primary percuta-
neous coronary intervention (pPCI) (TIMI grade 3 flow)
and absence of gross collateral flow by angiography. Fur-
thermore, patients should not have creatine kinase MB
(CKMB) or cardiac troponin T (cTnT) levels above clinical
reference values of MI before pPCI to minimize the influ-
ence of temporary opening of the occluded coronary
artery on final MI size [15].
Duration of ischemia was defined as time from onset of
chest pain, as reported by the patient, to opening of the
occluded coronary artery by pPCI. To decrease the risk of
including patients with false long duration of persistent
ischemia, the acuteness of the ischemia was also assessed
from the pre-PCI ECG using the previously described
Anderson-Wilkins (AW) electrocardiographic acuteness
score [16,17]. In short, an AW score between 1 and 4 was
designated to each patient, where 1 indicates the longest
and 4 indicates the shortest duration of persistent
ischemia. Presence of Q waves lower the AW score,
whereas tall T waves increase the AW score. Patients were
excluded from the analysis of time course of infarct evolu-
tion if they had more than three hours between pain onset
and pPCI and an AW score of 3 or higher. The AW acute-
ness score was performed by an experienced electrocardi-
ographer blinded to all other data.
Study protocol
For determination of MaR, 99mTc tetrofosmin was injected
approximately 5 minutes prior to opening of the occluded
artery by pPCI, and then the patients underwent MPS
within 3 hours. After the intervention the patients were
transferred to the coronary care unit for conventional
therapy, and had an uncomplicated clinical course
between the pPCI and the CMR examination performed
one week after admission for determination of MI size
and, for some of the patients, also MaR by T2-STIR imag-
ing.
Myocardial perfusion SPECT
Patients were injected with 500-700 MBq 99mTc tetrofos-
min (Amersham Health, Buckinghamshire, UK), depend-
ing on bodyweight. The ECG-gated MPS was performed
according to the standard clinical protocol at rest, using a
dual head-camera, either ADAC Vertex (Milpitas, Califor-
nia, USA) or a cardiac dedicated GE Ventri (GE Health-
care, Buckinghamshire, UK). The patients were placed in
supine position and imaged in steps of 5.6 degrees using
a 64 × 64 matrix with a pixel size of 5.02 mm for the
ADAC camera and a pixel size of 6.4 mm for the GE Ventri
camera. Image acquisition time was approximately 15Journal of Cardiovascular Magnetic Resonance 2009, 11:38 http://www.jcmr-online.com/content/11/1/38
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minutes. Short- and long-axis images gated to the ECG
were reconstructed using a commercial application (Aut-
oSpect+InStill™ 6.0, ADAC, Milpitas, California, USA).
Analysis of the perfusion defect for MaR was performed
using a freely available in-house developed segmentation
software (Segment v1.702; http://segment.heiberg.se).
The automatic segmentation finds the centreline through
the left ventricular wall and identifies the endo- and epi-
cardium based on an individually estimated wall thick-
ness and signal intensity values within the image [18].
Manual adjustment of the automatic delineation was
sometimes required in the left ventricular outflow region.
The perfusion defect was determined by an in-house
developed automated algorithm that considers myocar-
dium with < 55% of normal counts, taking into account
the different coronary perfusion territories, as being sub-
ject to ischemia (Soneson H, Engblom H, Hedstrom E,
Bouvier F, Sörensson P, Pernow J, Arheden H, Heiberg E:
A novel automatic method for quantification of myo-
cardium at risk from myocardial perfusion SPECT in
patients with acute coronary occlusion. Submitted).
Myocardium at risk was quantified as % of the left ventri-
cle.
CMR
One week after admission patients were imaged in the
supine position using either a 1.5 T system (Magnetom
Vision, Siemens, Erlangen, Germany) with a CP body
array coil or a 1.5 T system (Philips Intera CV, Philips,
Best, the Netherlands) with a cardiac synergy coil. Initial
scout images were acquired to locate the heart and T2-
weighted double inversion blood suppressed turbo spin
echo sequence (T2-STIR) was employed in 10 patients to
depict MaR as previously described [19]. T2-STIR images
were acquired in the short-axis view, covering the left ven-
tricle from the base to apex. Image parameters for T2-STIR
were: echo time of 43 ms (Siemens), or 100 ms (Philips);
repetition time, 2 heart beats; number of averages, 2;
inversion time of 180 ms; image resolution of 1.5 × 1.5 ×
10 mm (Siemens) or 1.5 × 1.5 × 8 mm with a slice gap of
2 mm (Philips). When acquiring images with the cardiac
synergy coil, parallel imaging with SENSE = 1 was used to
minimize signal inhomogeneities due to differences in
coil sensitivity. The MaR, defined as the region with
increased signal intensity in the short-axis T2-STIR images
[19], was manually delineated by two observers blinded
to all other data. A third independent observer was con-
sulted for consensus to enable comparison with infarct
evolution determined by MPS for assessment of MaR.
For infarct vizualisation, short- and long-axis LGE images
were acquired typically 20-30 minutes after administra-
tion of 0.2 mmol per kilogram of body weight of an extra-
cellular gadolinium-based contrast agent (gadoteric acid,
Gd-DOTA, Guerbet, Gothia Medical AB, Billdal, Sweden).
Acquisition was performed during breath-hold, using an
ECG-triggered segmented inversion-recovery gradient
recalled echo (IR-GRE) sequence. Typical IR-GRE
sequence parameters were: echo time/repetition time of 4/
8 ms; image resolution of 1.4 × 1.4 × 10 mm and flip angle
of 25° with acquisition every other heartbeat for the Sie-
mens scanner and echo time/repetition time of 1.2/3.9
ms; image resolution of 1.5 × 1.5 × 8 mm and flip angle
of 15° with acquisition every heartbeat for the Philips
scanner. The inversion time of typically 200-350 ms was
manually adjusted to null the signal from remote myocar-
dium.
Infarct quantification was performed on the short-axis
LGE images using the same software as for the MPS
images (Segment, v.1.702; http://segment.heiberg.se) by
employing a previously described automatic algorithm
for MI border detection [20]. The MI borders were visually
controlled and adjusted if the computer algorithm was
obviously wrong. Infarct transmurality was assessed using
a centerline approach, assessing the radial extent of hyper-
enhancement at each 4.5° from the center of each short-
axis slice. Infarct size was expressed as % of the left ventri-
cle. Infarct size by LGE was then normalized to MaR by
MPS and T2-STIR.
Comparison to previous animal studies
Species other than humans are frequently used in phase I-
II experiments, and canine work regarding myocardial cell
death beginning 30 minutes after occlusion is often
quoted. Therefore, it is important to compare the findings
from the present study in man with earlier results from
animal studies. For this purpose, analysis of MI size nor-
malized to MaR for rats [8,11], pigs [6,9], and dogs
[3,7,9,10] was performed and compared with the human
data in the present study.
Statistical analysis
The MI data as a function of duration of ischemia was
modelled by a simple function that embodies the follow-
ing features: After a short ischemic period the myocar-
dium is inviolate; after such a period the MI/MaR ratio
rises in a sigmoid fashion to a plateau level. The model
was constrained to the following form: MI/MaR at t min-
utes after occlusion = 100/(1+((T50-15)/(t-15))2), which
focuses on the time to 50% MI/MaR, T50. This function
was fitted by non-linear least-squares technique, and error
estimates on T50 obtained by first-order error propagation
[21]. These error estimates were calculated using data
from each species individually as well as using pooled
data. The former were used to obtain 95% confidence lev-
els for visual inspection, and the latter for multiple t-tests
with Sidak correction to test the separation between spe-
cies and between MPS and T2-STIR in terms of T50.Journal of Cardiovascular Magnetic Resonance 2009, 11:38 http://www.jcmr-online.com/content/11/1/38
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The relationship between the maximum infarct transmu-
rality and duration of ischemia was analyzed by the fol-
lowing sigmoidal model: Infarct transmurality after t
minutes = 100/(1+(Tr50/x)z), where Tr50 is time to 50%
transmurality, x the duration of ischemia and z the speed
at which MI transmurality progresses with increasing
duration of ischemia. This function was fitted by non-lin-
ear least-squares technique. The critical value of Student's
t distribution was used to derive the p-value for the corre-
lation between the function's prediction and measured
values. P-values < 0.05 were considered to indicate statis-
tical significance.
Results
Patient characteristics
Eighteen patients (17 men; 41-83 years) were prospec-
tively enrolled. Patient characteristics are presented in
Table 1. Duration of ischemia, AW score, MaR by MPS,
and MI size by LGE, are presented in Table 2. All patients
had ST elevation suggestive of acute myocardial ischemia
and underwent pPCI with stenting and received glycopro-
tein (GP) IIb/IIIa inhibitor resulting in TIMI grade 3 flow.
Two patients (#4 and #11, Table 2) reported more than 3
hours between pain onset and opening of the occluded
artery and had an AW score of 3 or higher. Therefore, these
two patients were excluded from further analysis. One
patient had 387 min between pain onset and opening of
the occluded artery. This patient had positive biomarkers
(CKMB 108 μg/l and cTnT 0.37 μg/l) before pPCI. How-
ever, since the artery was occluded at the time of angiog-
raphy, and that it is reasonable to believe that biomarkers
start to leak into the blood after more than 6 hours of
occlusion, this patient was included in the study.
Infarct size and myocardium at risk
The MI size by LGE was 7% (range 0-21%) of the left ven-
tricle. The MaR was 30% (range 5-48%) of left ventricle as
assessed by MPS and 32% (23-43%) of the left ventricle
on 10 of the 16 patients also assessed by T2-STIR. Interob-
server variability for determination of MaR by T2-STIR
was 1 ± 5 percentage units. Posterior wall signal loss and
increased signal intensity in the blood pool at the apical
parts of the left ventricule due to stagnant blood was fre-
quently seen in the T2-STIR short-axis images making the
determination of the endocardial and epicardial borders
challenging. This was solved by guidance from the short-
axis cine images in the corresponding level.
Infarct evolution in relation to duration of ischemia
Infarct size in relation to MaR was found to increase with
duration of ischemia (Figure 1A-D). Figure 2A shows that
the infarct evolution in man was considerably slower than
infarct evolution in rats (p < 0.001), pigs (p < 0.001) and
dogs (p < 0.01). The time to reach 50% MI of the MaR
(T50) was considerably shorter for pigs and rats (37 and 41
min, respectively) compared to dogs and humans (181
and 288 min, respectively) (Figure 2B). There was no sig-
nificant difference (p = 0.53) in T50 for the humans when
using MPS (288 ± 23 min) compared to T2-STIR (310 ± 22
min) for assessment of MaR (Figure 3).
In one patient (# 2, Table 2) with occlusion of the right
coronary artery, the MaR was not assessed due to lack of
MPS isotope. In this patient, biochemical markers of car-
diac injury were below reference level before pPCI and
rose to maximally 55 μg/l (CKMB) and 2.1 μg/l (cTnT)
after reperfusion. These findings indicate occlusion before
pPCI, successful reperfusion, and infarcted myocytes. This
patient had no MI visible by LGE and was therefore
included in the analyses as 0% MI of the MaR, although
no measurement of MaR was obtained.
Figure 4 shows that maximum MI transmurality increased
with increased duration of ischemia (R2 = 0.56; t = 4.3 cor-
responding to p < 0.001). The time to reach 50% transmu-
rality (Tr50) was 99 min.
Two examples of the infarct evolution normalized to MaR
in patients are shown in Figure 5.
Table 1: Patient characteristics
Age (years) 67 (41 - 83)
Male 17 (94%)
Culprit coronary artery
LAD 8 (44%)
LCx 1 (6%)
RCA 9 (50%)
TIMI grade 0 flow before pPCI 18 (100%)
TIMI grade 3 flow after pPCI 18 (100%)
Duration of ischemia (min) 158 (60 - 387)
MaR (% of left ventricle by MPS) 23 (5 - 48)
Infarct size (% of left ventricle) 7 (0 - 21)
Relative infarct size (% of MaR by MPS) 22 (0 - 54)
Previous angina pectoris 2 (11%)
Former smoker 9 (50%)
Active smoker 6 (33%)
ACE inhibitor 1 (6%)
Acetyl salicylic acid 2 (11%)
Angiotensin-II receptor blocker 1 (6%)
Beta blocker 0 (0%)
Calcium channel blocker 1 (6%)
Diuretic 2 (11%)
Statin 1 (6%)
Oral anti-diabetic 1 (6%)
Insulin 3 (17%)
Values as median (range) or frequency (%). ACE = angiotensin 
converting enzyme, LAD = left anterior descending coronary artery, 
LCx = left circumflex coronary artery, MaR = myocardium at risk, 
MPS = myocardial perfusion single photon emission computed 
tomography, pPCI = primary percutaneous coronary intervention, 
Rca = right coronary artery, TIMI = thrombolysis in myocardial 
infarction.Journal of Cardiovascular Magnetic Resonance 2009, 11:38 http://www.jcmr-online.com/content/11/1/38
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Discussion
This is the first study to provide direct evidence of the time
course of acute myocardial infarct evolution in relation to
MaR in man with first-time MI. Infarct evolution in man
is significantly slower than in pigs, rats and dogs. Further-
more, infarct evolution assessments in man are similar
when using MPS acutely and T2-STIR one week later for
determination of MaR, which significantly facilitates
future clinical trials of cardioprotective therapies in acute
coronary syndrome by the use of CMR.
In animal studies of the relationship between duration of
ischemia and MI size in relation to the MaR, the time of
coronary occlusion is very well defined. Also, the experi-
mental setting enables controlling that the coronary artery
remains occluded for the entire duration of ischemia.
Unlike the experimental setting, it is impossible to define
the exact time of occlusion in patients suffering from acute
coronary occlusion. Furthermore, spontaneous reper-
fusion and re-occlusion may occur between pain onset
and opening of the occluded artery by pPCI. In humans,
factors such as preinfarction angina, stuttering occlusion/
reperfusion, collateral blood flow, and many other factors
complicate precise determination of duration of ischemia.
In the present study, strict inclusion criteria were used to
limit analysis to patients with first-time MI, single
occluded artery at pPCI (TIMI 0), no angiographic evi-
dence of collaterals to the infarct-related territory, exclu-
sion of patients with elevated levels of biochemical
markers prior to pPCI, and patients where the reported
duration of ischemia corresponded with the AW acuteness
score that relates ECG findings to the duration of occlu-
sion. If indeed spontaneous reperfusion and re-occlusion
do occur, ischemic preconditioning may also explain why
no or only a small part of the MaR is eventually infarcted.
Thus many of these factors are critical when interpreting
the results.
Patients with visible collateral flow by angiography were
excluded from the present study to exclude patients with
prior ischemic heart disease. Small collaterals, not visible
by angiography, may still be present in patients included
in the present study. However, such a collateral flow
would not affect the measurement of MI size in relation to
MaR since the MaR, as assessed by MPS, by nature lacks
both native and collateral perfusion.
Late reperfusion has been shown to have a positive effect
on outcome after acute MI in man [22,23]. This may
partly be explained by spontaneous reperfusion and re-
occlusion occurring between pain onset and reperfusion
therapy. Thus, the time between pain onset and reper-
fusion by pPCI might not reflect the actual duration of
persistent ischemia. The present study directly demon-
strates that timely reperfusion is of importance to limit MI
size in humans, but also that late reperfusion in some
cases may salvage a significant amount of the MaR.
Currently, MPS is considered the reference technique for
quantifying MaR by injecting a perfusion tracer during
coronary occlusion followed by imaging shortly after the
reperfusion therapy. For assessment of MaR in acute coro-
nary occlusion, this technique requires intravenous injec-
tion of a technetium labeled perfusion tracer before the
Table 2: Duration of ischemia and corresponding AW-score, myocardium at risk and MI size.
Case Duration of ischemia (min) AW score MaR (% by SPECT) MI (%) MI/MaR (% by SPECT)
11 9 0 - † 37 11 31
2 60 3.1 - * 0 0
3 145 2.2 24 4 16
42 0 5 3 . 7 5 8 0 0
51 3 5 2 . 8 2 1 2 8
61 7 5 - † 52 4 0
7 80 2.8 32 9 29
8 245 2.7 25 8 31
91 1 0 3 . 0 4 8 2 4
10 135 4.0 24 2 7
11 240 3.0 71 7 10
12 150 1.0 29 11 37
13 96 3.2 34 0 0
14 195 -† 37 13 35
15 120 2.4 48 11 23
16 387 1.0 38 21 54
17 104 4.0 19 3 15
18 196 2.0 34 9 27
AW = Anderson-Wilkins score, MaR = myocardium at risk by SPECT. Infarct = infarct size by LGE.
* Please see Results for explanation, † AW scoring not possible.Journal of Cardiovascular Magnetic Resonance 2009, 11:38 http://www.jcmr-online.com/content/11/1/38
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Myocardial infarct size in relation to myocardium at risk with respect to duration of ischemia in different species Figure 1
Myocardial infarct size in relation to myocardium at risk with respect to duration of ischemia in different spe-
cies. A linear and logarithmic time scale is presented in the left and right panel, respectively. A: Data from previous studies in 
pigs (black circle = Fujiwara et al [9], white circle = Näslund et al [6]. B: Data from previous studies in rats (black circle = Hale 
et al [8], white circle Arheden et al [11]). C: Data from previous studies in dogs (white triangle = Reimer et al [3], black circle 
= Kloner et al [7], upward black triangle = Fujiwara et al [9], downward black triangle = Reimer et al [10]). D: Human data 
from the present study. The dashed lines represent the 95% confidence intervals. MaR = myocardium at risk; MI = myocardial 
infarction.Journal of Cardiovascular Magnetic Resonance 2009, 11:38 http://www.jcmr-online.com/content/11/1/38
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occluded artery is opened and a access to a gamma camera
within 3 hours of the injection. Consequently, the logis-
tics for such investigations are complicated and clinically
cumbersome [24]. Thus, there is a need for methods that
can be used to assess MaR remote to the time of the acute
event. It has previously been shown that T2-STIR can be
used to quantify MaR remote to the time of artery occlu-
sion in an experimental setting [25,26]. Friedrich et al [27]
have shown that T2-STIR can be employed in humans to
assess the amount of reversibly injured myocardium after
acute MI. Recently, Carlsson et al [19] validated T2-STIR
against MPS in humans and showed that the technique
can be used to assess MaR one week after an acute coro-
nary occlusion. In the present study, there was indeed no
difference in assessment of infarct evolution in man when
MaR was assessed acutely by MPS or one week after the
acute MI using T2-STIR. Hence, both MI size and MaR
and, consequently, myocardial salvage can be assessed at
the same CMR image session 1 week after the acute coro-
nary event, without interfering with patient care in the
acute situation. This enables evaluation of the efficiency
of interventions in acute coronary syndrome and the
Infarct progression for different species Figure 2
Infarct progression for different species. Comparison of the infarct progression slope (A) and the time to reach 50% MI 
of the MaR (B) for the different species. There was a significantly slower infarct evolution in man compared to pigs, rats and 
dogs. Consequently, the time to reach 50% MI of the MaR was longer for humans compared to pigs, rats and dogs. *** = p < 
0.001; ** = p < 0.01; MaR = myocardium at risk; MI = myocardial infarction.
Infarct evolution in man: MPS vs T2-STIR for myocardium at risk Figure 3
Infarct evolution in man: MPS vs T2-STIR for myocardium at risk. Infarct evolution when using (A) MPS and (B) T2-
STIR for assessment of MaR. The dashed lines represent the 95% confidence intervals in A and B. There was no significant dif-
ference between MPS and T2-STIR for assessing infarct evolution (C). MaR = myocardium at risk; MI = myocardial infarction; 
MPS = myocardial perfusion SPECT; T2-STIR = T2-weighted double inversion blood suppressed turbo spin echo CMR 
sequence.Journal of Cardiovascular Magnetic Resonance 2009, 11:38 http://www.jcmr-online.com/content/11/1/38
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opportunity to study infarct evolution several days after
the acute event. Image quality can, however, be a limita-
tion in assessing MaR by T2-STIR and the image quality of
the present study did not allow for automated segmenta-
tion. New sequences, however, are continuously devel-
oped to overcome this problem [28,29].
Comparison to animal studies
In order to compare the results from the present study
with results from previous animal studies, analysis of MI
size normalized to MaR versus duration of ischemia in dif-
ferent species [3,7-11] was performed (Figure 1, 2).
Since the degree of collateral flow is a proven modifier of
MI size [30-32], the difference in time course between spe-
cies could be explained by lack of collaterals in rats and
pigs, compared with more extensive collateral intercon-
nections in dogs [33]. It is generally accepted that collater-
als are present also in humans, however poorly developed
[34,35], and it has been shown in primates that only 20%
of MaR is infarcted after 90 minutes of occlusion [36].
This is in the same order of magnitude as the findings in
patients in the present study. Therefore, the differences
between species could also be explained by different pro-
tective mechanisms and different supply and demand of
the ischemic myocardium.
The increased MI transmurality with increased duration of
ischemia found in the present study has previously been
described as the "wavefront phenomenon" in dogs by
Reimer and Jennings [3]. In their study 50% transmurality
was reached sometime between 40 min and 180 min after
coronary occlusion, which is in the same order of magni-
tude of what was found in the present human study (99
min).
Limitations of the study
The number of studied patients is small. This was, how-
ever, the result of minimizing confounding factors to
achieve a study population that was as close to an experi-
mental setting as possible. The included patients thereby
yield results that are comparable to experimental animal
studies, which was the aim of the study.
Infarct size may also have been influenced by incomplete
reperfusion at the myocardial level even though TIMI
grade 3 flow was obtained at the time of pPCI in all
patients. To increase the probability of successful reper-
fusion even at the myocardial level, all patients received
GPIIb/IIIa inhibitor in conjunction with the pPCI. The
GPIIb/IIIa inhibitor has been presented as a promising
intervention in combination with PCI for preventing
obstruction of microvascular vessels [37].
The time from pain onset to opening of the artery used for
estimating the duration of ischemia has inherent limita-
tions as discussed above. However, in our opinion, this
study is as close to an experimental setting as possible
when studying clinical patients.
The MIs in the present study are modest in size (0-21% of
the left ventricle), and extrapolation to larger MIs cannot
be performed. The relatively small MI sizes could be
related to the relatively short duration of ischemia in the
Infarct transmurality in relation to duration of ischemia in  man Figure 4
Infarct transmurality in relation to duration of 
ischemia in man. As duration of ischemia increased the 
transmural extent of MI increased progressively. MI = myo-
cardial infarction.
Representative cases Figure 5
Representative cases. Fusion of polar plots from MPS 
acquired acutely and LGE images acquired one week after 
the acute MI in two patients subjected to ischemia for 110 
and 190 minutes, respectively. The MPS polar plots indicate 
MaR (black) in the otherwise well perfused myocardium (yel-
low). The center of the polar plot represents the left ven-
tricular apex and the periphery represents the basal parts of 
the left ventricle. Final MI size by LGE is shown in white, 
where brightness indicates MI transmurality from 0% (black) 
to 100% (white). LGE = late gadolinium enhancement; LV = 
left ventricle; MaR = myocardium at risk.Journal of Cardiovascular Magnetic Resonance 2009, 11:38 http://www.jcmr-online.com/content/11/1/38
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present study. The short duration of ischemia resulted
from short transportation distances and the aggressive
clinical approach by which the patients are transported by
ambulance directly to the catheterization laboratory.
The findings in the present study cannot be generalized to
infarct evolution in females, since only one female was
included in the study.
Conclusion
This is the first study to provide direct evidence of the time
course of acute myocardial infarct evolution in relation to
MaR in man with first-time MI. Infarct evolution in man
is significantly slower than in pigs, rats and dogs. Further-
more, infarct evolution assessments in man are similar
when using MPS acutely and T2-STIR one week later for
determination of MaR, which significantly facilitates
future clinical trials of cardioprotective therapies in acute
coronary syndrome by the use of CMR.
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